Clinical trials: Pick's Disease With Dementia
Alzheimer's Disease, Primary Progressive Non-fluent Aphasia
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
The purpose of this study is to determine safety, tolerability, and pharmacokinetics/dynamics of a ketogenic dietary supplement containing medium chain triglycerides (MCTs) in patients with Alzheimer disease (AD).
- Conditions
- Alzheimer's Disease, Primary Progressive Non-fluent Aphasia, Frontotemporal Dementia (FTD)
- Trial name
- MINT-01 (NCT02912936)
- Testing
- Ketogenic medium chain triglyceride drink (MCT drink)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- University of British Columbia
FTLD, Progressive Supranuclear Palsy (PSP)
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary…
- Conditions
- FTLD, Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD)
- Trial name
- ARTFL (NCT02365922)
- Where
- 17 sites in United States, Canada
- Volunteers
- 1,489 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
ALSFTD, ALS (Amyotrophic Lateral Sclerosis)
Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients
The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants…
- Conditions
- ALSFTD, ALS (Amyotrophic Lateral Sclerosis), Frontal Temporal Dementia (FTD)
- Trial name
- PROBIOTIC (NCT06051123)
- Testing
- Probiotic
- Where
- 3 sites in Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Amyotrophic Lateral Sclerosis, ALS
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).
- Trial name
- NCT05163886
- Testing
- LAM-002A
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- IRulya Therapeutics Inc.
Alzheimer Disease, Frontotemporal Dementia
Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases
Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases.
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Dementia With Lewy Bodies
- Trial name
- NCT05326750
- Testing
- Gamma tACS (40 Hz) over the superior parietal cortex
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- Kuopio University Hospital
Alzheimer's Disease, Progressive Primary Aphasia
tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia
The purpose of this study is to evaluate the effect of 10 sessions of anodal transcranial Direct Current Stimulation (tDCS - 1 mA) applied to left Cortex DorsoLateral PreFrontal (CDLPF) of Alzheimer's or Primary Progressive…
- Conditions
- Alzheimer's Disease, Progressive Primary Aphasia, Early or Mild State
- Trial name
- ALSTICO (NCT02873546)
- Testing
- transcranial Direct Current Stimulation (tDCS)
- Where
- 3 sites in France
- Volunteers
- 52 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Primary Progressive Nonfluent Aphasia
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
This study is a pilot trial evaluating the safety and immunogenicity of AADvac1 in patients with the non-fluent variant of Primary Progressive Aphasia.
- Trial name
- AIDA (NCT03174886)
- Testing
- AADvac1 40 µg, AADvac1 160 µg
- Where
- 3 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Axon Neuroscience SE
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the…
- Trial name
- NCT04993755
- Testing
- TPN-101, 400 mg/day
- Where
- 19 sites in United States, Belgium and 3 more
- Volunteers
- 42 people
- Sponsor
- Transposon Therapeutics, Inc.
Major Depressive Disorder (MDD), Schizophenia Disorder
Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders
This is a prospective observational study to identify sociodemographic factors that predict mental health outcomes in the European population and provide evidence linking common, modifiable sociodemographic risk factors for…
- Conditions
- Major Depressive Disorder (MDD), Schizophenia Disorder, Bipolar 1 Disorder, Alzheimer Disease
- Trial name
- Synapsing-SD (NCT07239843)
- Where
- Spain
- Volunteers
- 1,310 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Alzheimer's Disease
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
This follow-up study continues to observe patients who have completed the phase 1 trial of AADvac1, for another 18 months. Long-term safety and behavior of the immune response to AADvac1 over time are the main points of interest.
- Trial name
- FUNDAMANT (NCT02031198)
- Testing
- AADvac1
- Where
- 4 sites in Austria
- Volunteers
- 25 people
- Sponsor
- Axon Neuroscience SE
Apathy, Behavior
Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
The purpose of this study is to provide relevant quantitative evaluation of apathy close to real life situation by means of a multimodal sensor system integrated.
- Conditions
- Apathy, Behavior, Frontotemporal Dementia
- Trial name
- ECOCAPTURE (NCT02496312)
- Testing
- Evaluation of Apathy Close to Real Life Situation
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Primary Progressive Aphasia, Apraxia of Speech
Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation
The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., pre-supplementary motor area and left inferior frontal gyrus)…
- Trial name
- NCT05368350
- Testing
- high-definition transcranial direct current stimulation (HD-tDCS)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The University of Texas at Dallas
Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia
The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy
Background and objects Amyloid plaques and tau protein are the landmarks of neurodegeneration in Alzheimer's disease (AD). On the other hand, it is reported that cerebral ischemia may induce amyloid plaques and tau protein…
- Trial name
- NCT04309253
- Testing
- PMPBB3, AV45
- Where
- Taiwan
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Diabetes Mellitus, Type 2, Pre-diabetes
Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.
This is a single center brain Positron Emission Tomography (PET) study of 18F-MK-6240. Eligible participants are persons from Northern Manhattan who self-identify as Hispanic, non-Hispanic Black, or Non-Hispanic White, who are 55…
- Trial name
- NOMEM-Tau (NCT03389100)
- Testing
- 18F-MK6240 injection
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Columbia University
Alzheimer Disease, Parkinson Disease
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
- Trial name
- MemorEM (NCT07222605)
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- eQ8Health Corporation d/b/a CareONE Concierge
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
- Trial name
- NCT02880956
- Testing
- ABBV-8E12
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Alzheimer Disease, Preclinical Alzheimer's Disease
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological…
- Trial name
- TAURUS-1980 (NCT07158905)
- Testing
- AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Institute for Molecular Medicine
Neurodegenerative Diseases
Continuation Study for Latozinemab
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
- Trial name
- NCT06111014
- Testing
- Latozinemab
- Where
- 18 sites in United States, Belgium and 8 more
- Volunteers
- 17 people
- Sponsor
- Alector Inc.
Alzheimer Disease
Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
The recent development of a PET tracer,[18F]MK-6240(an[18F]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.
- Trial name
- MKADAD (NCT04104659)
- Testing
- MK 6240
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Frontotemporal Dementia
Flortaucipir PET Imaging in Subjects With FTD
This study is designed to assess the usefulness of flortaucipir in Positron Emission Tomography (PET) imaging for subjects diagnosed with Frontotemporal Dementia (FTD).
- Trial name
- NCT03040713
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Avid Radiopharmaceuticals